Analysis of Circulating Epithelial Tumor Cells in Peripheral Blood in Patients With Primary Non-metastatic Breast Cancer Under Adjuvant Radiotherapy

University of Jena161 enrolled

Overview

The aim of this study was to investigate the systemic effect of radiotherapy on patients with primary non-metastatic breast cancer using CETC and to analyze possible changes in CETC quantity under adjuvant radiotherapy.

In cooperation with the Women's Hospital of the Friedrich Schiller University in Jena, a total of 161 patients with clinically proven, primarily non-metastatic breast cancer were sampled and examined before and after radiotherapy over a period from 09/2002 to 09/2012. The MAINTRAC method was used to quantitatively determine the amount of CETC in the blood and to observe its peritherapeutic course.

Study Type

OBSERVATIONAL

Enrollment

161

Conditions

Breast Cancer Female

Interventions

radiationRADIATION

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed invasive breast carcinoma * age \>= 18 years * exclusive treatment at the Jena University Hospital * complete curative-intended adjuvant or definite radiotherapy * at least 2 blood collections (before the start of therapy, after the end of the RT) Exclusion Criteria: * presence of metastases * recurrence * DCIS, inflammatory breast cancer * second malignancy \<10 years before diagnosis of breast cancer * radiotherapeutic pretreatment

Locations (1)

Department of Radiooncology, Jena

Jena, Germany

Outcomes

Primary Outcomes

Overall survival

from the start of Radiotherapy until death / last seen during follow up

Time frame: up to 10 years

Secondary Outcomes

Disease free survival

from the start of Radiotherapy until relapse or metastasis / last seen during follow up

Time frame: up to 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.